The New Deal: Venture firm CMEA looks to bring drugs in-house, spin them out in 3 years or less

If Big Pharma is too big and biotechs are too small, CMEA Capital is working on a model that may be just right.
The San Francisco venture capital firm wants to move companies’ shelved drugs to an in-house team, contract out studies that take the drugs into mid-stage trials and sell to product-hungry companies in three years or less.
Taking a drug from Point A to Point B never looked so quick, cheap and easy. Now CMEA must make it work.